HSA permits sale of unaffected Medicube cream batches

AI-summarized · Neutrality-checked

The Singapore Health Sciences Authority (HSA) permitted the resumption of sales for unaffected batches of Medicube PDRN Pink Collagen Capsule Cream after testing confirmed they contained no Sudan IV dye. The regulatory action followed a July 31 suspension of sales for three distributors—APR SG, Venus Beauty, and Rirora International—after testing detected the banned carcinogenic dye in samples from Venus Beauty. Consequently, the HSA ordered a recall of specific Venus Beauty batches, identified as 2E122I.2E117I and 2E191G.2E193G, though no local adverse health effects were reported. Sudan IV is prohibited in cosmetics due to potential risks of genotoxicity and carcinogenic effects.

Consequences

To prevent future health risks, the HSA mandated that the three companies must now have every future batch of the product tested by an accredited laboratory and submit reports to the regulator before distribution. Companies that fail to comply with these safety and regulatory requirements face potential penalties of up to S$50,000 in fines, a two-year prison sentence, or both.

Sources

Know where. Know why.